TQ Quiz | Trending Topics in Neuro-Ophthalmic Disease (Nashville 2024) by Events@optometricedu.com | Sep 26, 2024 | 2024 Nashville, TQ Courses | 0 comments "*" indicates required fields HiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. Which of the following first generation MS drugs has the longest duration of action?* A - Plegridy B - Copaxone C - Betaseron D - Avonex 2. All of the following oral medications has a risk factor of cystoid macular edema EXCEPT:* A - Gilenya (fingolamod) B - Tecfidera (dimethyl fumarate) C - Mayzent (siponimod) D - Ponvory (ponesimod) 3. Which of the following MS drugs has the highest risk of PML?* A - Aubagio (teriflunamide) B - Gilenya (fingolamod) C - Tecfidera (dimethyl fumarate) D - Tysabri (natalizumab) 4. Which of the following inflammatory diseases is most likely to cause bilateral/simultaneous optic neuritis?* A - Myelin oligodendrocyte glycoprotein disease B - Multiple sclerosis C - Neuromyelitis optica D - Sarcoidosis 5. Which of the following is FDA approved for the systemic treatment of giant cell arteritis?* A - Actemra (tocilizumab) B - Rituxan (rituximab) C - Prednisone D - Tepezza (teprotumumab) 6. Which obesity related PTC patient with papilledema can be managed without medication?* A - Opening pressure of 450 mm H2O with no headaches and no impact on optic nerve structure or function B - Opening pressure of 280mmH2O with constant headaches and no impact on optic nerve structure or function C - Opening pressure of 300mmH20 with no headaches, arcuate VF loss and thinning of the GCC bilaterally D - Opening pressure of 310 mmH20 with no headaches and no impact on optic nerve structure or function 7. All of the following are true regarding Topiramate in the treatment of PTC EXCEPT:* A - It has been associated with angle closure secondary to choroidal effusion B - Its inhibition of carbonic anhydrase is superior to that of Diamox C - It has an important use in treating headaches associated with increased ICP D - It promotes weight loss 8. What amount of weight loss is generally considered to be effective in bringing about remission in obesity related PTC?* A - 3% B - 10% C - 15% D - 25% 9. An obese patient with chronic intracranial hypertension has been under your care for over a year. She is asymptomatic and is also non-compliant with Diamox due to side effects. Topamax was similarly problematic. She has persistent papilledema and is now demonstrating thinning of her GCC with arcuate visual field loss. What is the best management option?* A - Weight loss B - Bariatric surgery C - Optic nerve sheath fenestration D - Add prednisone to her medication regimen 10. A 250lb female with chronic intracranial hypertension has significant thickening of her RNFL on OCT. Her GCC/IPL is intact and her visual fields are normal. She has no visual symptoms and is not experiencing headaches. What is the most appropriate management plan?* A - Attempt weight reduction with a target weight of 225 lbs B - Diamox C - Topamax D - Bariatric surgery 11. A 250lb female with chronic intracranial hypertension has significant thickening of her RNFL on OCT . Her GCC/IPL is intact and her visual fields are normal. She has no visual symptoms, but is experiencing severe headaches. What is the most appropriate management?* A - 25 lb weight reduction without medication B - Diamox C - Topamax D - Bariatric surgery 12. A 250 lb female presents with severe headaches and bilateral disc edema that is consistent with papilledema. Her optic nerves demonstrate grade 5 papilledema and there are numerous hemorrhages and exudates. Blood pressure is 140/90. What is the most appropriate management plan?* A - Referral to the ER for emergent diagnostic work up B - Begin a high dosage of Diamox C - Begin treatment with Topamax D - Order an MRI and MRV, followed by a lumbar puncture 13. What is considered to be the gold standard in the diagnosis of myasthenia gravis?* A - Tensilon Test B - Antibody testing C - Thoracic CT D - EMG 14. All of the following are implicated in the pathophysiology of obesity related PTC EXCEPT:* A - Mechanical factors B - Cellular factors C - Endocrine factors D - Iron deficiency 15. Diagnostic testing for giant cell arteritis includes all of the following EXCEPT:* A - ESR/CRP B - TA Biopsy C - MR venogram D - Arterial ultrasound 16. All of the following are true regarding giant cell arteritis EXCEPT:* A - Fast track programs in emergency settings are useful in expediting diagnosis and treatment B - The carotid vasculature is the most frequent target of the vasculitic process C - Tocilizumab has been shown to reduce the dosage of prednisone and bring about more sustained remission D - Arteritic ischemic optic neuropathy shows rapid improvement with corticosteroids 17. All of the following are useful in the treatment of ocular myasthenia gravis EXCEPT:* A - Eculizumab (Solaris) B - Corticosteroids C - Mestinon D - Azothioprine 18. MRI findings suggestive of NMO occur in which part of the brain?* A - Periventricular B - Diencephalon/medulla C - Cerebellar D - Cerebral cortex 19. Which of the following is true regarding myasthenia gravis?* A - It affects involuntary muscle B - It has a predilection for muscles innervated by cranial nerves C - It has a variable presentation D - It is characterized by fatiguability 20. Which MS medication poses a risk to both male and female offspring?* A - Aubagio (teriflunamide) B - Gilenya (fingolimod) C - Vumerity (diroximel fumarate) D - Tecfidera (dimethyl fumarate) Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional Code Nashville 2024 - Trending Topics in Neuro-Ophthalmic Disease | TQ Credit*After 11/29/2024, pricing will increase to $30. Price: (Past 60 Days) Nashville 2024 - Trending Topics in Neuro-Ophthalmic Disease | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Credit Card* HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
